GALAPAGOS

GALAPAGOS is a clinical-stage biotechnology firm founded in 1999, specializing in the discovery and development of novel small molecule medicines. The company focuses on identifying and validating therapeutic targets to address significant unmet medical needs across various disease areas, including oncology. By leveraging proprietary genomic platforms, GALAPAGOS advances innovative drug discovery pipelines from initial identification through clinical-stage development.

Operating with a workforce of 1,000-5,000 employees, the organization maintains a robust operational footprint across 5 global locations. This scale supports their extensive research and development efforts, which involve over 100 scientists and specialized medical professionals. Meet GALAPAGOS's team to learn about their leadership and the technical expertise driving their clinical programs. The company’s commitment to scientific excellence is reflected in its diverse portfolio of therapeutic candidates and its strategic approach to pharmaceutical innovation.

Financially, GALAPAGOS demonstrates a strong market presence with annual revenue reaching $267.9M. The company has successfully utilized various capital-raising strategies, including stock issuances and share placements, to fund its ongoing research initiatives. Explore financial highlights for detailed metrics regarding their fiscal performance and investment history. As a publicly traded entity on the Euronext Amsterdam (AMS: GLPG), the firm continues to prioritize the advancement of its clinical-stage assets to deliver long-term value in the global healthcare sector.